Major depressive disorder and immunity to varicella-zoster virus in the elderly

Michael R. Irwin a,⁎, Myron J. Levin b, Carmen Carrillo a, Richard Olmstead a, Anne Lucko d, Nancy Lang b, Michael J. Caulfield e, Adriana Weinberg d, Ivan S.F. Chan e, Jim Clair e, Jeff G. Smith e, R.D. Marchese e, Heather M. Williams d, Danielle J. Beck d, Patricia T. McCook d, Gary Johnson c, Michael N. Oxman d,f

a Cousins Center for Psychoneuroimmunology, UCLA Semel Institute for Neuroscience and Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, United States
b University of Colorado Denver and Health Sciences Center, Aurora, CO, United States
c Veterans Affairs Cooperative Studies Program Coordinating Center, West Haven, CT, United States
d Department of Veterans Affairs San Diego Healthcare System, United States
e Merck Research Laboratories, Merck and Company, West Point, PA, United States
f University of California, San Diego, United States

⁎ Corresponding author. Address: Cousins Center for Psychoneuroimmunology, UCLA Semel Institute for Neuroscience, 300 UCLA Medical Plaza, Suite 3160A, Los Angeles, CA 90095-7057, United States. Fax: +1 310 794 9247.
E-mail address: Mirwin1@ucla.edu (M.R. Irwin).

ARTICLE INFO

Article history:
Received 22 November 2010
Received in revised form 2 February 2011
Accepted 2 February 2011
Available online 15 February 2011

Keywords:
Major depression
Elderly
Infectious disease
Herpes zoster
Cell-mediated immunity
Human
Stress

ABSTRACT

Major depressive disorder has been associated with activation of inflammatory processes as well as with reductions in innate, adaptive and non-specific immune responses. The objective of this study was to evaluate the association between major depression and a disease-relevant immunologic response, namely varicella-zoster virus (VZV)-specific immunity, in elderly adults. A cross-sectional cohort study was conducted in 104 elderly community dwelling adults ≥60 years of age who were enrolled in the depression substudy of the shingles prevention study, a double blind, placebo-controlled vaccine efficacy trial. Fifty-two subjects had a current major depressive disorder, and 52 age- and sex-matched controls had no history of depression or any mental illness. VZV-specific cell-mediated immunity (VZV-CMI) was measured by VZV responder cell frequency (VZV-RCF) and interferon-γ enzyme-linked immunospot (ELISPOT) assays, and antibody to VZV was measured by an enzyme-linked immunosorbent assay against affinity-purified VZV glycoproteins (gpELISA). VZV-CMI, measured by VZV-RCF, was significantly lower in depressed group than in the controls (p < 0.001), and VZV-RCF was inversely correlated with the severity of depressive symptoms in the depressed patients. In addition, an age-related reduction in VZV-RCF was observed in the depressed patients, but not in the controls. Furthermore, there was a trend for depressive symptom severity to be associated with lower ELISPOT counts. Finally, VZV-RCF was higher in depressed patients treated with antidepressant medications as compared to untreated depressed patients. Since lower levels of VZV-RCF appear to explain the increased risk and severity of herpes zoster observed in older adults, these findings suggest that, in addition to increasing age, depression may increase the risk and severity of herpes zoster.

© 2011 Elsevier Inc. All rights reserved.

1. Introduction

Herpes zoster, or shingles, is a painful neurocutaneous syndrome caused by reactivation and replication of varicella-zoster virus (VZV) that has remained latent in sensory neurons following varicella (Gilden et al., 2000; Gnann and Whitley, 2002; Hope-Simpson, 1965; Ragozzino et al., 1982). The incidence and severity of herpes zoster increase with advancing age in association with a progressive age-related decline in VZV-specific T cell-mediated immunity (VZV-CMI) (Berger et al., 1981; Burke et al., 1982; Levin et al., 1992; Miller, 1980). In the US, the incidence of herpes zoster exceeds 1% per year in persons ≥60 years of age; more than a million new cases occur each year; and one-third of the current population will experience herpes zoster during their lifetime – numbers destined to increase with the increasing age of the population (Donahue et al., 1995; Insinga et al., 2005; Oxman et al., 2005; Ragozzino et al., 1982). VZV-CMI is thought to play a critical role in protecting against herpes zoster and postherpetic neuralgia, and we have found that the magnitude and duration of the boost in VZV-CMI induced by zoster vaccine parallels the clinical effects of the vaccine observed during a large scale efficacy trial, the shingles prevention study (SPS) (Levin et al., 2008; Oxman et al., 2005; Weinberg et al., 2009). In contrast, antibody to VZV does not appear to protect against herpes zoster; levels of antibody to VZV do not decline with increasing age and higher levels of VZV-specific
antibody in subjects with herpes zoster in the SPS were correlated with increased disease severity and an increased risk of postherpetic neuralgia (Levin et al., 2008; Weinberg et al., 2009).

Among older adults, risk factors other than increasing age and lower levels of VZV-CMI have not been clearly identified, although psychological stress may play a role. In a retrospective, case-control study of 101 healthy community dwelling older adults, higher numbers of stressful life events were associated with a 2-fold increase in the risk of herpes zoster (Schmader et al., 1990), with similar findings reported in a prospective 8 year follow-up of 2568 adults (Schmader et al., 1998a). Whereas depression is associated with an activation of pro-inflammatory cytokines (Howren et al., 2009), other studies show that depression can reduce innate and adaptive cell-mediated immunity, although findings in the latter are limited (Irwin, 2008; Irwin and Miller, 2007). However, alterations in inflammation and innate immunity appear to be independent of one another, and increases in markers of inflammation are not associated with decreases in innate immunity in depression (Pike and Irwin, 2006).

Few studies have examined virus-specific immune responses in depression (Irwin, 2008; Irwin and Miller, 2007). Nevertheless, given that psychological stress can reduce immune responses to viral challenges (i.e., immunization) (Kiecolt-Glaser et al., 1996; Vedhara et al., 1999) and that psychological stress and depression appear to have similar effects on innate and virus-specific cellular-mediated immunity (CMI) (Irwin et al., 1990; Zorrilla et al., 2001), it was hypothesized that depression might reduce VZV-specific CMI in older adults who are at increased risk for herpes zoster and its complications. In a preliminary study, we reported that VZV-CMI was lower in eleven adults with major depression compared with eleven non-depressed age- and sex-matched controls (Irwin et al., 1998), although the conclusions were constrained by the small sample size and inclusion of only middle-aged adults. In the present study, measures of immunity to VZV were compared in depressed- and non-depressed adults ≥ 60 years of age, with examination of the effects of depressive symptom severity. Second, given that older age is associated with lower levels of VZV-CMI (Berger et al., 1981; Burke et al., 1982; Levin et al., 1992; Miller, 1980), and that depression and age interact such that depressed patients show a greater decline in non-specific immunity with age as compared to controls (Schleifer et al., 1989), we evaluated the associations between age and depression on VZV-immunity. Finally, the combined effects of depression and antidepressant medications on immunity to VZV were explored, because antidepressant medications appear to alter cellular immune responses in depressed patients (Evans et al., 2008; Tucker et al., 2004).

2. Methods

2.1. Subject population and study design

Department of Veterans Affairs (VA) Cooperative Study #403: the shingles prevention study (SPS) provided the data presented in this article (Oxman et al., 2005). The SPS was a 22 site, randomized, double-blind, placebo-controlled trial in 38,546 subjects ≥ 60 years of age, who received zoster vaccine or placebo and were subsequently observed for the development of herpes zoster and postherpetic neuralgia.

As part of the SPS eligibility requirements (Oxman et al., 2005), subjects were required to give written informed consent and to either have a history of varicella or at least 30 years of residence in the Continental United States. These criteria in persons ≥ 60 years of age ensured that virtually every subject was already latently infected with VZV (Harpaz et al., 2008). This expectation was supported by the observation that 100% of 1369 SPS subjects who were tested were found to be seropositive for VZV. We excluded immunocompromised persons who might be at risk from the live attenuated zoster vaccine and might not have a normal immunologic response to it. We also excluded persons with other conditions (e.g., chronic pain syndromes, cognitive impairment, and severe hearing loss) that would interfere with the evaluation of herpes zoster or compliance with protocol requirements (e.g., monthly automated telephonic response survey calls). Specific exclusion criteria were: (a) immunosuppressant resulting from disease (e.g., malignancy; HIV infection), corticosteroids (except intermittent topical or inhaled corticosteroid (<800 mcg/day beclomethasone dipropionate or equivalent)), or other immunosuppressive/cytotoxic therapy (cancer chemotherapy or organ transplantation); (b) active neoplastic disease (except local skin cancer or other malignancies (e.g., prostate cancer) that are stable in the absence of immunosuppressive/cytotoxic therapy); (c) prior herpes zoster (consequently, none of the subjects in the depression substudy had a history of herpes zoster); (d) prior receipt of varicella vaccine; (e) allergic sensitivity to neomycin; (f) history of anaphylactoid reaction to gelatin (g) significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 5 years); (h) subjects not ambulatory (i.e., bed-ridden or homebound); (i) receipt of immune globulin or any other blood product within 3 months before or planned during the 3–5 year study period; (j) receipt of any other immunizations within one month before study vaccination (2 weeks in the case of inactivated influenza vaccines or other non-replicating immunization products (e.g., DT, pneumococcal vaccine, hepatitis A vaccine, hepatitis B vaccine)), and scheduled within 6 weeks after study vaccination; (k) subjects currently receiving antiviral therapy; (l) any other condition (e.g., extensive psoriasis, chronic pain syndrome, cognitive impairment, severe hearing loss) that, in the opinion of the investigator, might interfere with the evaluations required by the study (m) subject with an intercurrent illness (e.g., urinary tract infection, influenza) that might interfere with the interpretation of the study (n) subjects who were female and pre-menopausal (women enrolled in the study were required to be postmenopausal); (o) subjects unlikely to adhere to protocol follow-up; (p) subjects involved in a conflicting (vaccine or investigational drug) clinical trial.

At two study sites, Denver, Colorado and San Diego, California, where the SPS core immunology laboratories were located, a total of 2850 subjects underwent SPS eligibility evaluation and depression screening between February 2000 and September 2001. Depression screening included completion of an abbreviated version of the Centers for Epidemiological Study of Depression (CES-D) scale (Irwin et al., 1999) and answering two questions about prior episodes of depression and/or treatment for depression. Of this eligible and screened sample, a total of 1395 subjects agreed to participate in the immunology substudy of the SPS, which involved assessment of VZV-specific immunity before vaccine or placebo administration, after 6 weeks, and after 1, 2, and 3 years. Once a subject agreed to participate in the immunology substudy, nursing coordinators reviewed depression screening information to identify subjects who screened positive for depressive symptoms and/or had a history of depression or depression treatment. In addition, after a subject was identified who was screened positive for depression, another subject who screened negative for depressive symptoms and/or depression history was identified (i.e., a comparison control); this comparison control, who was enrolled concurrently, was identified based on comparable age (± 3 years) and sex criteria. Together, these procedures yielded 341 subjects who screened positive for depression or depression history, and 349 age- and sex comparable subjects who screened negative for depression or depression history (i.e., comparison controls). A total of 212 screened depression positive-, and 219 screened depression
negative, comparison controls, agreed to participate in the depression substudy. All of these subjects completed clinical and psychiatric assessments including the Structured Clinical Interview for DSM-IV diagnosis (SCID-DSM-IV) (Spitzer et al., 1987); these interviews were completed on the day of entry in >95% of the participants.

Of the 212 persons who fulfilled screening criteria for depressive disorder or history of depression, SCID-DSM-IV interview data resulted in the exclusion of the following subjects: 2 for current alcohol dependence, 15 for current depression not otherwise specified (NOS) that also fulfilled criteria for the alternate label of minor depressive disorder, and 143 for a history of depression who did not fulfill diagnostic criteria for current major depression. Hence, 52 subjects who had current major depression were included in the study. Two of these patients were co-morbid for panic disorder; no other current psychiatric co-morbidities were diagnosed. None of the depressed subjects had a history of bipolar disorder.

Of the 219 persons who did not reach screening criteria for a depressive disorder or history of depression (i.e., comparison controls), 13 subjects were excluded by SCID-DSM-IV interview for past history of an Axis I disorder (e.g., alcohol dependence) and 6 for depression not otherwise specified. Thus, this control group represented a sample of older adults who had never been mentally ill (n = 200). To identify 52 comparison controls for inclusion in this study, control subjects were again matched with the depressed subjects using three criteria: age (±3 years), sex, and chronic disease score (CDS) stratified by quartile; matching procedures were done blind to VZV-immunity status as these immune data were maintained by the coordinating center of the SPS, separate from the depression substudy. Age, sex, and CDS were used as matching criteria, given the known effects of age- and sex use of medications and/or medical co-morbidities on cellular immune response. Hence, the present report focuses on the baseline VZV-CMI in the depression substudy (n = 104; 52 depressed subjects; 52 age-, sex-, and CDS comparable) where all measurements of immune response and severity of depression were obtained prior to inoculation in the Shingles Prevention Study. It should be emphasized that all of the depression substudy subjects were VZV seropositive before zoster vaccine or placebo vaccination. The Institutional Review Boards of the University of Colorado, University of California, San Diego (UCSD), and University of California, Los Angeles (UCLA) approved the depression substudy.

2.2. Clinical and psychiatric assessment

To evaluate medical eligibility, a trained nurse performed a medical history. Subjects with exclusionary medical conditions were not entered into the study; for eligible subjects, medical conditions were further classified into the following categories: hypertension, heart disease, chronic lung disease, asthma, diabetes, rheumatoid arthritis, cancer, and neurologic disorder based on history and self-reported medication use. In addition, to provide a measure of medical history that could be summarized as single score, the chronic disease score (CDS) questionnaire, a tabulation of medication usage, was administered as an interview by a nurse coordinator (von Korff et al., 1992). In addition, participants were instructed to bring their medication bottles and prescriptions to the study appointment, and the nurse coordinator recorded all medications used over the previous six months. Because the CDS does not include psychotropic or analgesic medications, this measure provides an estimate of medical history independent of psychiatric and pain-related symptoms.

The SCID-DSM-IV (First et al., 1996) was administered by trained doctoral level psychiatric nurses. Interview data were presented in a weekly diagnostic consensus teleconference that included at least two psychiatric nurses, a board-eligible psychologist, and a board-certified psychiatrist (MRI). The meeting was shared across sites to minimize diagnostic drift and maintain a consistent approach to resolving diagnostic ambiguities. Over the course of the study, periodic viewing and scoring of videotaped interviews were implemented to maintain reliability and criterion validity. Information about the clinical characteristics of the major depressive episode was obtained, including duration of current episode, number of prior episodes, and medication treatment history. Depression severity was assessed by administration of the beck depression inventory (BDI) (Beck et al., 1966). The Pittsburgh sleep quality index (PSQI) was used to assess sleep quality (Buysse et al., 1989).

Blood samples were obtained by venipuncture between 8:00 and 10:00 AM on the same day that the clinical and psychiatric assessments were completed in >95% of the depression substudy sample; RCF assays were performed and PBMC frozen for ELISPOT assays within 2 h of sample acquisition by a technician blind to the subjects’ group allocation.

2.3. Immunologic assessments

VZV-specific responder cell frequency (RCF) assay, interferon-γ enzyme-linked immunospot (ELISPOT) assay, and enzyme-linked immunosorbent assay against affinity-purified VZV glycoproteins (gpELISA) were performed as described elsewhere (Hayward et al., 1994; Irwin et al., 1998, 2007; Weinberg et al., 2009), and as described here briefly.

2.3.1. Responder cell frequency (RCF) assay

For RCF, the frequency of circulating VZV-specific CD4+ T cells was measured by adding a limiting dilution step to a lymphoproliferative assay (Hayward et al., 1994; Irwin et al., 1998; Oxman et al., 2005; Weinberg et al., 2009). Twofold dilutions of peripheral blood mononuclear cells (PBMCs) between 50,000 and 1,563 cells/well were added to 24 replicate microtiter wells containing VZV-infected human lung fibroblast lysate or 24 replicate microtiter wells containing mock-infected control antigens. Responding wells were defined as VZV-stimulated wells with tritiatedthymidine–measured proliferation at least 3 standard deviations (SDs) above the median for the 24 mock-stimulated wells at the same PBMC concentration or 3-fold higher than that median if it was <100 counts per minute. On the basis of the Poisson distribution, the RCF was defined as the cell concentration at which 37% of wells were nonresponders and was expressed as the number of VZV-responding cells per 10^5 PBMCs. The analytic sensitivity of this test has been conventionally considered >1 responding cell/10^5 PBMCs. A mathematical model predicted a sensitivity of >0.2 responding cells/10^5 PBMCs. Statistical analyses using either of these thresholds showed similar results. Here, we report the results of analyses that used the conservative threshold of 1 responding cell/10^5 PBMCs. Values below this limit were recorded as 0.5 responding cell/10^5 PBMCs to minimize the potential for introducing biases due to biologically insignificant assay variability.

2.3.2. ELISPOT assay

ELISPOT assay was used to measure the frequency of VZV-specific interferon-γ-producing PBMCs, expressed as spot forming cells (SFCs) per 10^6 PBMCs as previously validated (Smith et al., 2001). Previously cryopreserved PBMCs at 500,000 cells/well were stimulated in triplicate wells with VZV lysate, mock-infected control, or phytohemagglutinin. After overnight incubation, wells were stained for γ interferon and SFCs were counted with an ImmunoSpot Analyzer (Cellular Technology). Valid assays were defined as those with >500 phytohemagglutinin-stimulated SFCs/10^6 PBMCs. VZV-specific SFCs were calculated as SFCs in VZV-stimulated wells minus SFCs in control-stimulated wells. Values
3. Results

3.1. Subject characteristics

The controls and depressed subjects were similar in demographic characteristics including age, gender, ethnicity, educational level, and marital and employment status. (Table 1) In addition, similar levels of medical co-morbidity were found in the controls and depressed patients with similar rates of hypertension (31% vs. 36%), heart disease (19.2% vs. 19.2%), chronic lung disease (2% vs. 2%), asthma (2% vs. 2%), and diabetes (6% vs. 6%), with no reported rheumatoid arthritis, cancer, or neurologic disorder in the two groups. Additionally, medication usage across various medical co-morbidities was comparable for the two groups as indicated by scores on the chronic disease scale for regular prescription medications use. As indicated by the frequency of medical co-morbidities, common medications were anti-hypertensive and cardiovascular medications including diuretics and beta-blocker agents, and oral hypoglycemic medication for the control of diabetes. The depressed subjects reported significantly more depressive symptoms as measured by the Beck depression inventory, as well as significantly greater disturbances in sleep quality, as measured by the Pittsburgh sleep quality index. There were only two current tobacco smokers in this sample, both in the depressed group.

Table 1

Demographic variables, chronic disease scores, severity of depressive symptoms, sleep quality, and VZV-immunity in depressed patients and controls.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Control (n = 52)</th>
<th>Major depression (n = 52)</th>
<th>Depression effect</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic disease score</td>
<td>68.4</td>
<td>6.1</td>
<td>68.4</td>
</tr>
<tr>
<td>Depressive symptoms (BDI scores)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sleep quality (PSQI scores)</td>
<td>2.7</td>
<td>2.5</td>
<td>16.5</td>
</tr>
<tr>
<td>VZV-RCF (log)</td>
<td>1.0</td>
<td>0.3</td>
<td>0.7</td>
</tr>
<tr>
<td>VZV-ELISPOT (log)</td>
<td>1.6</td>
<td>0.7</td>
<td>1.4</td>
</tr>
<tr>
<td>VZV gpELISA (log)</td>
<td>2.4</td>
<td>0.4</td>
<td>2.5</td>
</tr>
<tr>
<td>N %</td>
<td></td>
<td></td>
<td>N %</td>
</tr>
<tr>
<td>Gender (female)</td>
<td>31%</td>
<td>60%</td>
<td>31%</td>
</tr>
<tr>
<td>Ethnicity (Euro-American)</td>
<td>48%</td>
<td>92%</td>
<td>49%</td>
</tr>
<tr>
<td>Educational level (college graduate)</td>
<td>26%</td>
<td>50%</td>
<td>22%</td>
</tr>
<tr>
<td>Marital status (married)</td>
<td>32%</td>
<td>62%</td>
<td>26%</td>
</tr>
<tr>
<td>Employment status (employed)</td>
<td>22%</td>
<td>42%</td>
<td>18%</td>
</tr>
</tbody>
</table>

<1 SFC/10^6 PBMCs were recorded as 0.5 SFC/10^6 PBMCs (Smith et al., 2001).

2.3.3. Glycoprotein ELISA (gpELISA)

VZV-gpELISA was used to measure the VZV-specific antibody concentration (Hammond et al., 2006). This assay measures antibodies against affinity-purified VZV glycoproteins. At baseline, all subjects had titers 15 gpELISA units/mL, the level considered seroprotective against varicella in varicella vaccine recipients (Li et al., 2002). ELISPOT assay and gpELISA were performed at Merck Research Laboratories, and RCF assay was performed at Denver and San Diego.

2.4. Statistical analyses

Analyses were carried out with SPSS for Windows, version 15. The distribution of VZV-RCF, ELISPOT, and gpELISA data was skewed, and thus analyses for these variables employed natural log transformations. Differences between depressed and non-depressed (control) subjects in background and clinical variables, as well as VZV-RCF, ELISPOT counts, and gpELISA titers, were analyzed using chi-square tests. Pearson correlation coefficients were used to assess the association between background and clinical variables and VZV-RCF, ELISPOT, and gpELISA. Variables that were associated (p < 0.10) with both major depression and VZV-RCF, ELISPOT, or gpELISA levels were selected as covariates, and analysis of covariance was used to test the independent association between depression diagnosis and each of these indices of VZV-specific immunity, controlling for significant covariates (p < 0.10), with evaluation of the effects of age, depressive symptom severity, and their interaction on depression diagnosis given prior findings that such factors interact to influence immunity in depression (Schleifer et al., 1989). Exploratory analyses using ANOVA and ANCOVA models evaluated differences in VZV-RCF between non-depressed controls and depressed patients, stratified by the use of antidepressant medications.

3.2. Varicella-zoster virus-specific immunity and depression

The depressed subjects had lower levels of VZV-RCF as compared to controls (t = 3.2, p = 0.002) (Fig. 1 and Table 1). However,
neither ELISPOT counts nor gpELISA titers differed between the two groups (Table 1).

ANCOVA analyses were used to evaluate whether the effects of depression on VZV-RCF are attributable to depression diagnosis, severity of depressive symptoms, and/or the interaction of depression diagnosis and severity of depressive symptoms, taking into account the additional effects of age, sex, medical co-morbidity (as indexed by CDS scores), and sleep quality. In addition, given prior findings that age is associated with VZV-RCF, and that age and depression interact to predict lower levels of cellular immunity (Schleifer et al., 1989), we also evaluated the interaction between age and depression diagnosis within this ANCOVA model. As shown in Table 2, VZV-RCF was significantly associated with sex ($F(1,88) = 13.73$, $p < 0.001$) and depression diagnosis ($F(1,88) = 10.77$, $p = 0.002$). There was a trend for antidepressant medication use ($F(1,88) = 3.53$, $p < .07$) and a trend for positive psychological symptoms ($F(1,88) = 10.4$, $p = 0.002$), with a trend toward having a lower mean level of VZV-RCF than the depressed subjects who were taking antidepressant medications ($t = 2.0, p = 0.06$). The two depressed groups were similar in age, ethnicity, educational level, employment status, and chronic disease scores ($p > 0.30$). Interestingly, depressive symptom severity was similar in the medicated and non-medicated depressed groups ($15.7 \pm 9.1$ and $17.5 \pm 7.8$, respectively; $t = 0.7, p = 0.46$). Additional ANCOVA analyses were used to evaluate the effects of antidepressant medication use on VZV-RCF in the depressed group only (i.e., none of the controls were receiving antidepressant medications) taking into account the additional effects of age, sex, medical co-morbidity (as indexed by CDS scores), depressive symptoms, and sleep quality. Within the depression group only, VZV-RCF was related to age ($F(1,40) = 10.4; p < 0.01$) and sex ($F(1,40) = 5.0; p = 0.05$), with a trend for antidepressant medication use ($F(1,40) = 2.8; p = 0.10$), but not with chronic disease scores ($F(1,40) = 0.8; p = 0.39$), depressive symptom severity ($F(1,40) = 0.8; p = 0.39$), nor sleep quality ($F(1,40) = 0.64; p = 0.43$). There was no interaction between antidepressant medication status and depressive symptom severity on VZV-RCF.

### Table 2

Predictors of VZV-RCF in depressed patients and controls.

<table>
<thead>
<tr>
<th>Predictor</th>
<th>$F$</th>
<th>$B^*$</th>
<th>$p$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>3.53</td>
<td>-0.032</td>
<td>0.07</td>
</tr>
<tr>
<td>Sex (male vs. female)</td>
<td>13.73</td>
<td>-0.276</td>
<td>0.001</td>
</tr>
<tr>
<td>Medical co-morbidity, Chronic disease score</td>
<td>0.17</td>
<td>0.007</td>
<td>0.69</td>
</tr>
<tr>
<td>Sleep quality, PSQI scores</td>
<td>0.40</td>
<td>-0.007</td>
<td>0.54</td>
</tr>
<tr>
<td>Depressive symptom severity, BDI scores</td>
<td>1.05</td>
<td>-0.008</td>
<td>0.31</td>
</tr>
<tr>
<td>Age x depression diagnosis</td>
<td>10.16</td>
<td>-2.684</td>
<td>0.002</td>
</tr>
<tr>
<td>Age x depression diagnosis</td>
<td>10.77</td>
<td>0.039</td>
<td>0.001</td>
</tr>
<tr>
<td>Depressive symptom severity x depression diagnosis</td>
<td>3.20</td>
<td>0.037</td>
<td>0.08</td>
</tr>
</tbody>
</table>

* For control group.

#### 3.3. Effect of antidepressant medication use

Because the use of antidepressant medications (e.g., selective serotonin reuptake inhibitors) has been associated with alterations of innate and adaptive cellular immune responses (Evans et al., 2008; Tucker et al., 2004), exploratory analyses were conducted in which the depressed patients were stratified on the basis of current use ($n = 29$) or non-use ($n = 23$) of antidepressant medication. None of the control subjects were using antidepressant medications. VZV-RCF differed across the three groups ($F(2103) = 7.6, p < 0.001$; Fig. 4). Depressed subjects not on antidepressants had the lowest mean level of VZV-RCF, which was significantly lower than the mean level of VZV-RCF in the controls ($t = 4.0, p < 0.001$), with a trend toward having a lower mean level of VZV-RCF than the depressed subjects who were taking antidepressant medications ($t = 2.0, p = 0.06$). The two depressed groups were similar in age, ethnicity, educational level, employment status, and chronic disease scores ($p > 0.30$). Interestingly, depressive symptom severity was similar in the medicated and non-medicated depressed groups ($15.7 \pm 9.1$ and $17.5 \pm 7.8$, respectively; $t = 0.7, p = 0.46$). Additional ANCOVA analyses were used to evaluate the effects of antidepressant medication use on VZV-RCF in the depressed group only (i.e., none of the controls were receiving antidepressant medications) taking into account the additional effects of age, sex, medical co-morbidity (as indexed by CDS scores), depressive symptoms, and sleep quality. Within the depression group only, VZV-RCF was related to age ($F(1,40) = 10.4; p < 0.01$) and sex ($F(1,40) = 5.0; p = 0.05$), with a trend for antidepressant medication use ($F(1,40) = 2.8; p = 0.10$), but not with chronic disease scores ($F(1,40) = 0.8; p = 0.39$), depressive symptom severity ($F(1,40) = 0.8; p = 0.39$), nor sleep quality ($F(1,40) = 0.64; p = 0.43$). There was no interaction between antidepressant medication status and depressive symptom severity on VZV-RCF.

---

Fig. 2. Varicella-zoster virus specific responder cell frequency (VZV-RCF) differentially related to age for those with major depressive disorder (●) and controls (○).
4. Discussion

The markedly increased risk for herpes zoster and its complications observed among older adults is associated with an age-related decline in VZV-CMI, as exemplified by declining VZV-RCF. This study demonstrated that VZV-RCF was further reduced in older persons with current major depressive disorder compared with non-depressed age-, sex-, and CDS comparable controls. Furthermore, age interacted with depression diagnosis, and an age-related reduction of VZV-RCF was observed in the depressed patients but not in the controls; a finding that is consistent with prior work by Schleifer et al. (1989). Moreover, severity of depressive symptoms appeared to be associated with the extent of the reduction in VZV-RCF in the depressed patients, but not in the controls, in whom depressive symptoms were uncommon. Similarly, the severity of depressive symptoms also appeared to be associated with lower γ-interferon ELISPOT counts, another index of VZV-CMI, although that relationship did not reach statistical significance. Finally, in the depressed group, VZV-RCF was lowest in depressed subjects who were not receiving treatment with antidepressant medications, an effect that could not be accounted for by differences in depressive symptom severity. This may have been because the subjects who were on antidepressant treatment but were still symptomatic for depression were refractory to treatment.

These immunologic findings suggest that depressed adults may be at increased risk for herpes zoster compared with non-depressed adults of the same age. Higher levels of VZV-CMI, measured by VZV-RCF, have been shown to be a robust predictor of protection against the occurrence and severity of herpes zoster and its complications, particularly the development of postherpetic neuralgia (Weinberg et al., 2009). We previously reported that serial measurements of VZV-RCF were higher in subjects who did not develop herpes zoster than in those who did, and that higher levels of VZV-RCF prior to the onset of herpes zoster were predictive of higher levels of VZV-RCF during the first week after herpes zoster onset (Weinberg et al., 2009). Importantly, higher levels of VZV-RCF in the first week after the onset of herpes zoster were correlated with reduced herpes zoster severity and with a reduced risk of postherpetic neuralgia (Weinberg et al., 2009). Furthermore, it was observed that subjects who developed herpes zoster during the SPS follow-up period developed and maintained higher levels of VZV-RCF than subjects who had not developed herpes zoster (Weinberg et al., 2009), which provides a potential explanation for the clinical observation that one episode of herpes zoster reduces the risk that the afflicted individual will suffer a subsequent attack (Yawn et al., 2007).

The findings that depression is associated with reduced levels of VZV-RCF may have broader implications for the risk of other infectious diseases. VZV–RCF measures primarily VZV-specific memory T-cells (CD41 CD45RO1 T-cells) (Hayward, 2001), and the association between depression and lower numbers of circulating VZV-specific memory T cells, as suggested by our observation of lower levels of VZV-RCF in depressed patients, may extend to memory T-cells specific for antigens of other pathogens that cause disease in older adults, such as influenza viruses and Mycobacteria. However, few studies have examined the association between...
depression and infectious disease and/or disease-relevant immunologic endpoints. Rather, studies have characterized the effects of psychological stress, as opposed to depression, on these outcomes (Irwin and Miller, 2007). For example, psychological stress is associated with an attenuated immune response to influenza vaccines in older adults (Kiecolt-Glaser et al., 1996; Vedhara et al., 1999). Additionally, psychological stress is associated with infectious disease such as activation of genital herpes (Cohen et al., 1999). Furthermore, HIV infection shows a highly variable course, and depression, bereavement, and maladaptive coping responses to stress (including the stress of HIV infection itself) have all been shown to predict the rate of immune system decay in HIV patients (Cruess et al., 2005) and to predict mortality in the case of social stress (Cole et al., 2003).

Although previous studies demonstrated that VZV-RCF and ELISPOT counts were modestly correlated with each other (Levin et al., 2008; Weinberg et al., 2009), we found that only VZV-RCF was reduced in subjects with depression, although there was a trend for ELISPOT counts to be negatively associated with depressive symptom severity. This difference may reflect a selective effect of depression on a broad spectrum of VZV-specific memory T-cells, which are not measured by the γ-interferon ELISPOT assay.

In contrast to VZV-RCF, VZV antibody levels were not reduced in depressed subjects. Psychological stress and depression have been found to be associated with a reactivation of Herpesviruses, including Epstein Barr virus, herpes simplex viruses, and VZV (Glaser and Kiecolt-Glaser, 2005; Glaser et al., 1993; Schmader et al., 1998a,b; Schmader et al., 1990). When viral reactivation is coupled with low levels of CMI, the virus is not fully contained and the proliferating virus results in an antigenic stimulus that can increase titers of antibody to the reactivated virus. We speculate that subjects with depression who had lower levels of VZV-specific memory T-cells may have been more likely to develop herpetic zoster when VZV reactivated, to have experienced VZV replication, and thus to develop elevated levels of antibodies to VZV. However, because individuals with prior herpes zoster were not eligible for the SPS, we excluded subjects in whom reactivations of VZV would have resulted in higher levels of antibodies to VZV. In other words, subjects eligible for the present study did not have prior episodes of herpes zoster, which would have resulted in increased levels of antibodies to VZV. Additionally, we and others have shown that VZV antibody levels are not highly correlated with levels of VZV-CMI (Levin et al., 2008). For example, with aging there is a decrease in VZV-CMI, whereas VZV antibody titers remain relatively intact (Oxman and Alani, 1993). Moreover, in subjects receiving immunization for herpetic zoster, there was no correlation between levels of antibodies to VZV and VZV-CMI at baseline or after immunization, possibly due to the fact that B cells and T cells respond to different VZV epitopes (Weinberg et al., 2009).

The mechanism(s) that account for the reduction of VZV-RCF in depressed elderly adults are unknown, although our finding that treatment with SSRI tends to be associated with partial normalization of lower levels of VZV-RCF observed in depressed subjects suggests that alterations in the activity of central serotoninergic pathways may play a role. As noted, SSRI treatment was not associated with differences in depressive symptom severity. Our observations are consistent with those of Evans et al., who found that treatment with the SSRI, citalopram, enhanced natural killer cell activity in HIV-infected subjects, independent of effects on depressive symptom severity (Evans et al., 2008). Other data suggest that SSRI-treatment is associated with a normalization of inflammatory cytokine levels (e.g., IL-1β) in patients with post-traumatic stress disorder (Tucker et al., 2004). Alternatively, we and others have found that sleep disturbance, prevalent in persons with depressive disorders, has a robust and independent effect on innate immune and inflammatory responses (Irwin et al., 1996, 2006, 2008; O’Connor et al., 2009), and increases the risk of viral infections (Cohen et al., 2009). Indeed, in the present study, severity of neurovegetative symptoms and poor sleep quality were associated with reduced levels of VZV-RCF.

Further research is needed to evaluate the possible relationship between depression and the risk of herpes zoster. This will require a large number of subjects because of the relatively low annual incidence of herpes zoster (approximately 10–12 cases per 1000 persons per year in persons ≥60 years of age (Oxman et al., 2005). However, the finding that the well-documented age-related reduction in VZV-RCF was further reduced by depression in elderly individuals has important public health implications. The elderly are already prioritized for zoster vaccination because of their relatively low levels of VZV-CMI and their associated increased risk for herpes zoster and its complications (Harpaz et al., 2008; Oxman, 2010). The clinical efficacy of zoster vaccine is correlated with its capacity to boost VZV-specific CMI, and vaccine recipients with higher baseline levels of VZV-CMI have been shown to achieve higher absolute levels of VZV-CMI in response to vaccination. Thus, depressed elderly adults may have a diminished capacity to develop effective levels of VZV-CMI in response to zoster vaccine, and might require immunization with a higher potency vaccine or, possibly, with a multi-dose schedule. Further analyses of results from the depression substudy will address this hypothesis by comparing the magnitude and durability of the VZV-CMI response to zoster vaccine in our depressed and non-depressed subjects.

Financial disclosure information

The authors have no financial interest related to the outcome of this research, and have no potential conflicts of interest. Dr. Levin receives research funds, consultation fees, and royalties from intellectual property from Merck and Co.

Acknowledgments

This work was supported by MH 55253 and in part by VA Cooperative Study Program, Office of Research and Development, Department of Veterans Affairs; a grant from Merck & Co., Inc. to the VA Cooperative Studies Program; NIH Grants: T32-MH19925; HL 079955; AG 026364; CA 10014152; CA116778; RR08027; and P30-AG028748. Additional support is acknowledged from the General Clinical Research Centers Program; the UCLA Cousins Center for Psychoneuroimmunology at the Semel Institute for Neurosciences; the UCLA Older Americans Independence Center Inflammatory Biology Core; and the James R. and Jesse V. Scott Fund for Shingles Research.

References
